Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FH3X
|
|||
| Former ID |
DNC006109
|
|||
| Drug Name |
A-437203
|
|||
| Synonyms |
ABT-925 anhydrous free base; A-437203; 220519-06-2; UNII-E6CKI5C54O; E6CKI5C54O; CHEMBL439338; 2-((3-(4-(2-(tert-Butyl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)propyl)thio)pyrimidin-4(3H)-one; ABT-925 free base; SCHEMBL1043144; DTXSID70176529; BDBM50177354; HY-U00185; AKOS027334456; CS-7258; LU-201640; LU 201640; A 37203; A-37203; L018707; 4(3H)-Pyrimidinone, 2-((3-(4-(2-(1,1-dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl)-1-piperazinyl)propyl)thio)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Psychotic disorder [ICD-11: 6A20-6A25] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H27F3N6OS
|
|||
| Canonical SMILES |
CC(C)(C)C1=NC(=CC(=N1)N2CCN(CC2)CCCSC3=NC=CC(=O)N3)C(F)(F)F
|
|||
| InChI |
1S/C20H27F3N6OS/c1-19(2,3)17-25-14(20(21,22)23)13-15(26-17)29-10-8-28(9-11-29)7-4-12-31-18-24-6-5-16(30)27-18/h5-6,13H,4,7-12H2,1-3H3,(H,24,27,30)
|
|||
| InChIKey |
KXVAICSRMHXLJN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 220519-06-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine D3 receptor (D3R) | Target Info | Modulator | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Dopaminergic synapse | ||||
| Reactome | Dopamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Nicotine Activity on Dopaminergic Neurons | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012940) | |||
| REF 2 | Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response.Transl Psychiatry.2013 Apr 9;3:e245. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.